Trial Outcomes & Findings for Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery (NCT NCT00967447)
NCT ID: NCT00967447
Last Updated: 2025-02-11
Results Overview
TERMINATED
2 participants
6 Months
2025-02-11
Participant Flow
Only two patients were included into the study. The sponsor decided to finish it due to a delay of recruitment period.
Participant milestones
| Measure |
Dabigatran Exilate 220 Once Daily (OD)
10 days for Knee Replacement or 28-35 Hip Replacement
|
|---|---|
|
Overall Study
STARTED
|
2
|
|
Overall Study
COMPLETED
|
2
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 6 MonthsPopulation: The trial was stopped due poor enrollment
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: From 12 To 37 DaysPopulation: The trial was stopped due poor enrollment
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: From 12 To 37 DaysPopulation: The trial was stopped due poor enrollment
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: From 12 To 37 DaysPopulation: The trial was stopped due poor enrollment
Outcome measures
Outcome data not reported
Adverse Events
Dabigatran Exilate 220 Once Daily (OD)
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Boehringer Ingelheim Call Center
Boehringer Ingelheim Pharmaceuticals
Results disclosure agreements
- Principal investigator is a sponsor employee Any publication of the results of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract
- Publication restrictions are in place
Restriction type: OTHER